

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): September 02, 2026**

---

**Attovia Therapeutics, Inc.**

(Exact name of Registrant as Specified in Its Charter)

---

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-43423**  
(Commission File Number)

**92-1510574**  
(IRS Employer  
Identification No.)

**1091 Industrial Road  
Suite 310  
San Carlos, California**  
(Address of Principal Executive Offices)

**94070**  
(Zip Code)

**Registrant's Telephone Number, Including Area Code: 510 399-5001**

(Former Name or Former Address, if Changed Since Last Report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

| <b>Title of each class</b>                 | <b>Trading<br/>Symbol(s)</b> | <b>Name of each exchange on which registered</b> |
|--------------------------------------------|------------------------------|--------------------------------------------------|
| Common stock, \$0.0001 par value per share | ATTO                         | The Nasdaq Stock Market LLC                      |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

---

**Item 2.02 Results of Operations and Financial Condition.**

On September 2, 2026, Attovia Therapeutics, Inc. (the “Company”) issued a press release reporting its financial results for the second quarter ended June 30, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section or Section 11 or 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), nor shall it be deemed incorporated by reference into any filing by the Company under the Exchange Act or the Securities Act, whether made before or after the date hereof, except as expressly set forth by reference in such filing.

**Item 9.01 Financial Statements and Exhibits.**

| Exhibit<br>Number | Description                                                                         |
|-------------------|-------------------------------------------------------------------------------------|
| 99.1              | <a href="#">Press Release announcing financial results, dated September 2, 2026</a> |
| 104               | Cover Page Interactive Data File (embedded within the Inline XBRL document)         |

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Attovia Therapeutics, Inc.**

Date: September 2, 2026

By: /s/ Tao Fu

**Tao Fu**  
**Chief Executive Officer, President and Director**  
*(Principal Executive Officer)*

---



## **Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update**

*ATTO-1310 demonstrated preliminary clinical proof of concept in chronic pruritus and high-itch atopic dermatitis (AD); complete Phase 1b data expected in Q4 2026*

*Phase 2 studies of ATTO-1310 in chronic pruritus of unknown origin and high-itch AD planned for 1H 2027*

*Phase 1 initiation for ATTO-2306 and ATTO-1091 planned in 1H 2027*

*Upsized Initial Public Offering (IPO) gross proceeds of \$332.4 million helps extend cash runway into 2030*

**SAN CARLOS, Calif., September 2, 2026** – Attovia Therapeutics, Inc. (“Attovia” or the “Company”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today reported financial results for the second quarter ended June 30, 2026 and provided a corporate update.

“Following the successful completion of our upsized IPO, Attovia enters its next exciting phase with a strong balance sheet and clear line of sight to multiple potential near-term value-creating milestones,” said Tao Fu, Founder and Chief Executive Officer of Attovia. “The preliminary clinical proof of concept for ATTO-1310 in chronic pruritus and high-itch AD provides important validation of both the program and our ATTOBODY platform. We are advancing ATTO-1310 toward two large Phase 2 studies while progressing ATTO-2306 and ATTO-1091 toward the clinic in the first half of 2027. With multiple internally discovered programs moving through development, we remain focused on disciplined execution and building Attovia into a sustainable, multi-product biotechnology company with the goal of shaping the future of immune-mediated diseases.”

### **Recent Pipeline Highlights and Upcoming Milestones**

**ATTO-1310 for pruritic diseases:** a novel, highly potent, half-life extended ATTOBODY-based Fc-fusion protein targeting the itch cytokine IL-31.

- Completed the Phase 1a study in healthy volunteers in which ATTO-1310 demonstrated favorable tolerability, rapid and sustained suppression of IL-31, and low immunogenicity.
  - Completed enrollment and dosing in the double-blind, placebo-controlled Phase 1b study in patients with chronic pruritus and high-itch AD. Preliminary results showed that a single dose of ATTO-1310 was followed by rapid, deep itch relief in both patient populations, and consistent lesion control was demonstrated in patients with high-itch AD, providing clinical proof of concept for ATTO-1310 and the ATTOBODY platform. Complete Phase 1b data are expected in the fourth quarter of 2026.
  - Submitted the protocol for the global Phase 2 study in patients with chronic pruritus of unknown origin (CPUO) to the U.S. Food and Drug Administration (FDA) after incorporating the agency’s feedback on key design elements and endpoints. Study initiation is planned for the first half of 2027.
  - Global Phase 2 study in patients with high-itch AD is planned to initiate in the first half of 2027.
-

- Received IND clearance for Phase 1b trial in patients with cholestatic pruritus associated with primary biliary cholangitis (PBC) or primary sclerosing cholangitis (PSC) in China in less than 30 working days via National Medical Products Administration (NMPA)'s new expedited review pathway.

**ATTO-2306 for AD and other immune-mediated skin diseases:** a highly potent, half-life extended ATTOBODY-based bispecific antibody targeting IL-31 and IL-13.

- In preclinical studies, ATTO-2306 demonstrated highly potent inhibition of IL-31 and IL-13, long half-life, and low immunogenicity risk.
- IND-enabling activities are ongoing with Phase 1 initiation expected in the first half of 2027.

**ATTO-1091 for inflammatory bowel disease:** a next-generation ATTOBODY-based trispecific designed to target TL1A, IL-23p19, and integrin  $\alpha 4\beta 7$ .

- In preclinical studies, ATTO-1091 demonstrated potent inhibition of all three targets, low immunogenicity risk and favorable developability properties.
- IND-enabling activities are ongoing with Phase 1 initiation expected in the first half of 2027.

#### Early-stage pipeline

- Advanced ATTO-006, a conditional “AND-gated” bispecific tissue-resident memory T cell (Trm) survival blocker for a broad range of immune-mediated diseases, toward development candidate nomination by year-end 2026.

#### Corporate Highlights

- Completed an upsized IPO with aggregate gross proceeds of approximately \$332.4 million, before deducting underwriting discounts and commissions and other offering expenses. The Company's common stock is now trading on the Nasdaq Global Market under the ticker symbol “ATTO”.
- Strengthened the Board of Directors with the appointment of John W. Smither, a proven financial leader with extensive public company board and audit committee experience.

#### Second Quarter Financial Results

**Revenue:** Collaboration revenue for the quarter ended June 30, 2026 was \$0.5 million, attributable to research and development services provided under the EndPath RadioTherapeutics license agreement, compared to no collaboration revenue in the second quarter of 2025.

**Cash Position:** Cash, cash equivalents and marketable securities were \$115.1 million as of June 30, 2026, compared to \$152.3 million as of December 31, 2025. The Company expects that its current cash, cash equivalents and marketable securities, including the net proceeds from the IPO completed in August 2026 of approximately \$305.4 million, will enable it to fund its operations into 2030.

**Research & Development (R&D) Expenses:** Research and development expenses were \$18.9 million for the quarter ended June 30, 2026, compared to \$13.6 million for the second quarter of 2025. The increase in R&D expenses was primarily driven by clinical, manufacturing and preclinical costs to advance ATTO-1310 toward completion of its Phase 1 trial, and manufacturing and preclinical costs to advance ATTO-2306 and ATTO-1091 in IND-enabling activities.

**General & Administrative (G&A) Expenses:** General and administrative expenses were \$3.3 million for the quarter ended June 30, 2026, compared to \$3.0 million for the second quarter of 2025. The slight increase in G&A expenses was primarily due to higher personnel costs to support the Company's growth and public company readiness activities.

**Net Loss:** Net loss was \$20.7 million for the quarter ended June 30, 2026, as compared to \$14.4 million for the second quarter of 2025.

---

## About Attovia Therapeutics, Inc.

Attovia™ is a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need. All of its product candidates have been internally discovered using its ATTOBODY™ biparatopic biologics platform. Attovia's ATTOBODY platform uses an evolution-driven, high-throughput process that allows for rapid discovery and creation of a high diversity of potential product candidates.

Attovia's lead programs include ATTO-1310, an anti-IL-31 therapeutic in clinical development for chronic pruritic diseases; ATTO-2306, a bispecific antibody targeting IL-31 and IL-13 in IND-enabling studies for atopic dermatitis and other immune-mediated skin diseases; and ATTO-1091, a trispecific antibody targeting TL1A, IL-23p19, and integrin  $\alpha 4\beta 7$  in IND-enabling studies for inflammatory bowel disease. Attovia's other programs include highly innovative conditional 'AND' gated bispecific immune cell survival blockers and multispecifics.

## Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the current beliefs and expectations of management. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, without limitation, statements concerning the Company's future plans and prospects; any expectations regarding the safety or efficacy of ATTO-1310, ATTO-2306, and ATTO-1091, and other candidates under development; the ability of such candidates to treat their indications; the planned timing of the Company's clinical trials, data results and further development of its product candidates; the sufficiency of the Company's current cash, cash equivalents and marketable securities to fund its operations; and the Company's expected cash runway. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "will," "predict" and similar expressions and their variants, as they relate to the Company may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although the Company believes the expectations reflected in such forward-looking statements are reasonable, the Company can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied in the Company's forward-looking statements due to a variety of factors, including risks and uncertainties related to the Company's ability to advance its product candidates and obtain regulatory approval of and ultimately commercialize such product candidates, the timing and results of preclinical studies and clinical trials, the Company's ability to fund development activities and achieve development goals, its ability to protect its intellectual property, general business and economic conditions, and risks related to the impact on its business of macroeconomic and geopolitical conditions, including inflation, volatile interest rates, tariffs, instability in the global banking sector, public health crises, and geopolitical conflicts. Further information on potential risk factors that could affect the Company's business and its financial results are detailed under the heading "Risk Factors" included in the documents the Company files from time to time with the U.S. Securities and Exchange Commission. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date of this press release and Attovia undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

## Investor and Media Contact

Attovia Therapeutics  
[ir@attovia.com](mailto:ir@attovia.com)

PJ Kelleher  
LifeSci Advisors LLC  
617-430-7579  
[pkelleher@lifesciadvisors.com](mailto:pkelleher@lifesciadvisors.com)

---

**Attovia Therapeutics, Inc.**  
**Condensed Consolidated Balance Sheets (unaudited)**  
**(in thousands, except share and per share amounts)**

|                                                   | June 30, 2026 | December 31, 2025 |
|---------------------------------------------------|---------------|-------------------|
| Cash, cash equivalents, and marketable securities | \$ 115,132    | \$ 152,268        |
| Total assets                                      | 128,348       | 165,893           |
| Total liabilities                                 | 15,581        | 15,103            |
| Total redeemable convertible preferred stock      | 258,226       | 258,226           |
| Total stockholders' deficit                       | (145,459)     | (107,436)         |

**Attovia Therapeutics, Inc.**  
**Condensed Consolidated Statements of Operations (unaudited)**  
(in thousands, except share and per share amounts)

|                                                                                   | Three Months Ended June 30, |             | Six Months Ended June 30, |             |
|-----------------------------------------------------------------------------------|-----------------------------|-------------|---------------------------|-------------|
|                                                                                   | 2026                        | 2025        | 2026                      | 2025        |
| Revenue                                                                           |                             |             |                           |             |
| Collaboration revenue                                                             | \$ 450                      | \$ —        | \$ 450                    | \$ —        |
| Total revenue                                                                     | 450                         | —           | 450                       | —           |
| Operating expenses                                                                |                             |             |                           |             |
| Research and development                                                          | \$ 18,946                   | \$ 13,588   | \$ 35,692                 | \$ 25,444   |
| General and administrative                                                        | 3,307                       | 3,032       | 6,516                     | 7,280       |
| Total operating expenses                                                          | 22,253                      | 16,620      | 42,208                    | 32,724      |
| Loss from operations                                                              | (21,803)                    | (16,620)    | (41,758)                  | (32,724)    |
| Other income (expense):                                                           |                             |             |                           |             |
| Interest income                                                                   | 1,141                       | 2,041       | 2,467                     | 3,167       |
| Change in fair value of preferred stock tranche liability                         | —                           | —           | —                         | (170)       |
| Other income (expense), net                                                       | (25)                        | 140         | (52)                      | 137         |
| Total other income (expense), net                                                 | 1,116                       | 2,181       | 2,415                     | 3,134       |
| Net loss                                                                          | \$ (20,687)                 | \$ (14,439) | \$ (39,343)               | \$ (29,590) |
| Less: Accretion of redeemable convertible preferred stock to its redemption value | —                           | —           | —                         | (271)       |
| Net loss attributable to common stockholders                                      | \$ (20,687)                 | \$ (14,439) | \$ (39,343)               | \$ (29,861) |
| Net loss per share attributable to common stockholders, basic and diluted         | \$ (4.88)                   | \$ (3.71)   | \$ (9.38)                 | \$ (7.75)   |
| Weighted-average common shares outstanding, basic and diluted                     | 4,237,597                   | 3,895,037   | 4,195,615                 | 3,851,124   |

